Iijima, Hiroaki
Tanabe Pharma Corporation (Japan)
3 papers on CoChatORCID 0000-0003-4621-2394
Most cited papers
- Verified
Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 140
- Verified
Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus
Iijima, H., Kifuji, T., Maruyama, N., & Inagaki, N. (2015) · Advances in Therapy
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 70
- Verified
Associations between eating habits and glycemic control and obesity in Japanese workers with type 2 diabetes mellitus
Gouda, M., Matsukawa, M., & Iijima, H. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Nutrition, Health and Food BehaviorDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 46
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free